NEW YORK — Australian diagnostics firm Genetic Technologies said on Thursday that it has signed definitive agreements to sell approximately $6.6 million of its American Depository Shares (ADSs) to undisclosed institutional investors.
Through the registered direct offering, Genetic Technologies said it will sell 1.25 million ADSs, each representing 600 of its ordinary shares, at a price of $5.25 each. The offering is expected to close next week, with HC Wainwright acting as the exclusive placement agent.